Skip to main content

Grafa News and Videos — Page 1192

Latest

Grafa

Corbus advances nectin-4 cancer asset toward registrational trials

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) released updated Phase 1/2 clinical data for its experimental antibody-drug conjugate, CRB-701, demonstrating therapeutic activity in patients with pretreated, human papillomavirus (HPV)-associated solid tumors that express high levels of the Nectin-4 protein.

Read more: Corbus advances nectin-4 cancer asset toward registrational trials
Grafa

Dyne Therapeutics seeks FDA accelerated approval for muscular dystrophy drug

Dyne Therapeutics (NASDAQ:DYN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking conditional marketing clearance for z-rostudirsen, its investigational treatment targeting a specific subset of patients with Duchenne muscular dystrophy (DMD).

Read more: Dyne Therapeutics seeks FDA accelerated approval for muscular dystrophy drug
Grafa
Industrials

CSW Industrials posts record fiscal 2026 sales on acquisition surge

CSW Industrials (NYSE:CSW) reported record financial results for both the fourth quarter and the full fiscal year of 2026, navigating higher interest expenses and non-cash charges through a combination of aggressive acquisition integration and a return to organic expansion in its core segment.

Read more: CSW Industrials posts record fiscal 2026 sales on acquisition surge
Grafa

Freightos gross booking value surges 24% as higher rates offset volume headwinds

Freightos (NASDAQ:CRGO) reported mixed financial and operational metrics for the first quarter of 2026, as geopolitical tensions and airspace restrictions across the Middle East slowed core transaction growth while simultaneously driving up global shipping rates to support the logistics platform's overall transaction value.

Read more: Freightos gross booking value surges 24% as higher rates offset volume headwinds
Grafa

Genprex pinpoints key biomarkers to predict Reqorsa gene therapy success at ASCO

Genprex (NASDAQ:GNPX) announced the official abstract publication of positive clinical biomarker data for its lead oncology candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Read more: Genprex pinpoints key biomarkers to predict Reqorsa gene therapy success at ASCO
Grafa

Biohaven seizure drug extends remission in broad clinical data update

Biohaven (NYSE:BHVN) released new clinical and safety data for opakalim, its selective Kv7.2/7.3 potassium channel activator, showing meaningful reductions in seizure frequency and a highly differentiated central nervous system safety profile across generalized and focal forms of epilepsy.

Read more: Biohaven seizure drug extends remission in broad clinical data update

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift